Circulating Immunome Fingerprint in Eosinophilic Esophagitis is Associated with Clinical Response to Proton Pump Inhibitor Treatment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Apr 22

PMID 38646544

Authors

Lola Ugalde-Trivino

Francisca Molina-Jimenez

Juan H-Vazquez

Carlos Relano-Ruperez

Laura Arias-Gonzalez

Sergio Casabona

Maria Teresa Perez-Fernandez

Veronica Martin-Dominguez

Jennifer Fernandez-Pacheco

Alfredo J Lucendo

David Bernardo

Cecilio Santander

Pedro Majano

Affiliations

Soon will be listed here.

Abstract

Objectives: The aim of the study was to characterize the circulating immunome of patients with EoE before and after proton pump inhibitor (PPI) treatment in order to identify potential non-invasive biomarkers of treatment response.

Methods: PBMCs from 19 healthy controls and 24 EoE patients were studied using a 39-plex spectral cytometry panel. The plasmacytoid dendritic cell (pDC) population was differentially characterized by spectral cytometry analysis and immunofluorescence assays in esophageal biopsies from 7 healthy controls and 13 EoE patients.

Results: Interestingly, EoE patients at baseline had lower levels of circulating pDC compared with controls. Before treatment, patients with EoE who responded to PPI therapy had higher levels of circulating pDC and classical monocytes, compared with non-responders. Moreover, following PPI therapy pDC levels were increased in all EoE patients, while normal levels were only restored in PPI-responding patients. Finally, circulating pDC levels inversely correlated with peak eosinophil count and pDC count in esophageal biopsies. The number of tissue pDCs significantly increased during active EoE, being even higher in non-responder patients when compared to responder patients pre-PPI. pDC levels decreased after PPI intake, being further restored almost to control levels in responder patients post-PPI.

Conclusions: We hereby describe a unique immune fingerprint of EoE patients at diagnosis. Moreover, circulating pDC may be also used as a novel non-invasive biomarker to predict subsequent response to PPI treatment.

Citing Articles

Complex immune network and regional consistency in the human gastric mucosa revealed by high-resolution spectral cytometry.

De Prado A, Cal-Sabater P, Fiz-Lopez A, Izquierdo S, Corrales D, Perez-Cozar F Sci Rep. 2024; 14(1):28685.

PMID: 39562636 PMC: 11577052. DOI: 10.1038/s41598-024-78908-z.

References

Kohrgruber N, Groger M, Meraner P, Kriehuber E, Petzelbauer P, Brandt S . Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J Immunol. 2004; 173(11):6592-602. DOI: 10.4049/jimmunol.173.11.6592. View

Lucendo A, Molina-Infante J, Arias A, von Arnim U, Bredenoord A, Bussmann C . Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017; 5(3):335-358. PMC: 5415218. DOI: 10.1177/2050640616689525. View

Chang J, Saini S, Mellinger J, Chen J, Zikmund-Fisher B, Rubenstein J . Management of eosinophilic esophagitis is often discordant with guidelines and not patient-centered: results of a survey of gastroenterologists. Dis Esophagus. 2019; 32(6). PMC: 6561423. DOI: 10.1093/dote/doy133. View

Lin J, Wu W, Chen J, Liu I, Chiu H, Chen H . Plasmacytoid dendritic cells suppress Th2 responses induced by epicutaneous sensitization. Immunol Cell Biol. 2020; 98(3):215-228. DOI: 10.1111/imcb.12315. View

Rochman M, Azouz N, Rothenberg M . Epithelial origin of eosinophilic esophagitis. J Allergy Clin Immunol. 2018; 142(1):10-23. PMC: 8034427. DOI: 10.1016/j.jaci.2018.05.008. View

Gonzalez-Cervera J, Arias A, Redondo-Gonzalez O, Cano-Mollinedo M, Terreehorst I, Lucendo A . Association between atopic manifestations and eosinophilic esophagitis: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017; 118(5):582-590.e2. DOI: 10.1016/j.anai.2017.02.006. View

Albanesi C, Scarponi C, Pallotta S, Daniele R, Bosisio D, Madonna S . Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med. 2008; 206(1):249-58. PMC: 2626680. DOI: 10.1084/jem.20080129. View

Rossi C, Lenti M, Di Sabatino A . The need for a reliable non-invasive diagnostic biomarker for eosinophilic oesophagitis. Lancet Gastroenterol Hepatol. 2022; 7(3):202-203. DOI: 10.1016/S2468-1253(21)00468-4. View

Navarro P, Arias A, Arias-Gonzalez L, Laserna-Mendieta E, Ruiz-Ponce M, Lucendo A . Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019; 49(9):1116-1125. DOI: 10.1111/apt.15231. View

10.

Seth S, Oberdorfer L, Hyde R, Hoff K, Thies V, Worbs T . CCR7 essentially contributes to the homing of plasmacytoid dendritic cells to lymph nodes under steady-state as well as inflammatory conditions. J Immunol. 2011; 186(6):3364-72. DOI: 10.4049/jimmunol.1002598. View

11.

Hirano I, Chan E, Rank M, Sharaf R, Stollman N, Stukus D . AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology. 2020; 158(6):1776-1786. PMC: 9473154. DOI: 10.1053/j.gastro.2020.02.038. View

12.

Perez-Lucendo I, Gomez Torrijos E, Donado P, Melero R, Feo-Brito F, Urra J . Low Expression of ICAM-1 in Blood Eosinophils in Patients With Active Eosinophilic Esophagitis. J Investig Allergol Clin Immunol. 2020; 31(4):316-321. DOI: 10.18176/jiaci.0489. View

13.

Gruden E, Kienzl M, Ristic D, Kindler O, Kaspret D, Schmid S . Mononuclear cell composition and activation in blood and mucosal tissue of eosinophilic esophagitis. Front Immunol. 2024; 15:1347259. PMC: 10839056. DOI: 10.3389/fimmu.2024.1347259. View

14.

Molina-Infante J, Lucendo A . Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: A Paradigm Shift. Am J Gastroenterol. 2017; 112(12):1770-1773. DOI: 10.1038/ajg.2017.404. View

15.

Lucendo A, Molina-Infante J . Limitation of Symptoms as Predictors of Remission in Eosinophilic Esophagitis: The Need to Go Beyond Endoscopy and Histology. Gastroenterology. 2016; 150(3):547-9. DOI: 10.1053/j.gastro.2016.01.014. View

16.

Molina-Jimenez F, Ugalde-Trivino L, Arias-Gonzalez L, Armenteros E, Relano-Ruperez C, Casabona S . Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response. Allergy. 2024; 79(12):3448-3463. PMC: 11657045. DOI: 10.1111/all.16261. View

17.

Greuter T, Alexander J, Straumann A, Katzka D . Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis- Current Concepts and Perspectives for Steroid Use. Clin Transl Gastroenterol. 2019; 9(12):e212. PMC: 6303250. DOI: 10.1038/s41424-018-0074-8. View

18.

Uchida A, Burk C, Rothenberg M, Furuta G, Spergel J . Recent Advances in the Treatment of Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2023; 11(9):2654-2663. PMC: 10530275. DOI: 10.1016/j.jaip.2023.06.035. View

19.

Massironi S, Mulinacci G, Gallo C, Elvevi A, Danese S, Invernizzi P . Mechanistic Insights into Eosinophilic Esophagitis: Therapies Targeting Pathophysiological Mechanisms. Cells. 2023; 12(20). PMC: 10605530. DOI: 10.3390/cells12202473. View

20.

Vanbervliet B, Bendriss-Vermare N, Massacrier C, Homey B, de Bouteiller O, Briere F . The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med. 2003; 198(5):823-30. PMC: 2194187. DOI: 10.1084/jem.20020437. View